Sedef Hande AKTAŞ, Büşra EMİR, Dilara Fatma AKIN BALI, Ozan YAZICI

Survivin As an Immunohistochemical Prognostic Biomarker in Colorectal Cancer: A Meta-Analysis

OBJECTIVE Genome-level research qualifies survivin as the fourth-best “transcriptome” for colon, lung, brain, breast, and melanoma cancers. To date, it has been stated as a prognostic marker and therapeutic target in colorectal cancer (CRC). However, researchers on survivin expression in CRC are heterogeneous. Our current study aimed to reveal prognostic importance of survivin by investigating all CRC articles up to January 2021 that have performed analysis of survivin by immunohistochemical staining method. METHODS A comprehensive literature search for relevant studies published up to January 2021 was performed using SCOPUS and Pubmed databases. Only articles in which survivin was detected by IHC stain- ing were included in the study. All analyses were conducted by using Comprehensive Meta-Analysis. Eight articles and data of 1535 patients were included in the study. The Hazard Ratio was used to examine the relationship between CRC and survivin protein, for the relative weights of each research article. HR and 95% confidence interval values and general summary HR were calculated and forest plot graph was obtained. RESULTS Statistical heterogeneity Cochrane’s Q test statistics 24.156; p=0.004 and I2 value was obtained as 62,742. In line with the assumption that the data consisted of different populations, the HR and 95% CI values were calculated as 1.446 (1.103-1.897) using the Dersimonian and Laird random effects model. In order to evaluate the risk of publication bias, funnel plots were obtained, including log HR and standard error values on the x and y axes, respectively. CONCLUSION The analyzes obtained suggest that survivin overexpression in CRC is associated with poor prognosis. (HR=1.446; 95% CI: 1.103-1.897).

PDF

___

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjo- mataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mor- tality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209–49.
2. Hoff PM, Cassidy J, Schmoll HJ. The evolution of flu- oropyrimidine therapy: from intravenous to oral. On- cologist 2001;6 (Suppl 4):3–11.
3. Crook NE, Clem RJ, Miller LK. An apoptosis-inhibit- ing baculovirus gene with a zinc finger-like motif. J Virol 1993;67(4):2168–74.
4. Ambrosini G, Adida C, Altieri DC. A novel anti-apop- tosis gene, survivin, expressed in cancer and lym- phoma. Nat Med 1997;3(8):917–21.
5. Jaiswal PK, Goel A, Mittal RD. Survivin: A molec- ular biomarker in cancer. Indian J Med Res 2015;141(4):389–97.
6. Garg H, Suri P, Gupta JC, Talwar GP, Dubey S. Sur- vivin: a unique target for tumor therapy. Cancer Cell Int 2016;16:49.
7. Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 2001;7(12):542–7.
8. Liu JL, Gao W, Kang QM, Zhang XJ, Yang SG. Prog- nostic value of survivin in patients with gastric can- cer: a systematic review with meta-analysis. Plos One 2013;8(8):e71930.
9. Amur S, LaVange L, Zineh I, Buckman-Garner S, Woodcock J. Biomarker qualification: toward a mul- tiple stakeholder framework for biomarker develop- ment, regulatory acceptance, and utilization. Clin Pharmacol Ther 2015;98(1):34–46.
10. Oh HH, Joo YE. Novel biomarkers for the diagno- sis and prognosis of colorectal cancer. Intest Res 2020;18(2):168–83.
11. Xu L, Zhou X, Xu L, Yin R. Survivin rs9904341 (G>C) polymorphism contributes to cancer risk: an updated meta-analysis of 26 studies. Tumour Biol 2014;35(2):1661–9.
12. Huang YJ, Qi WX, He AN, Sun YJ, Shen Z, Yao Y. The prognostic value of survivin expression in patients with colorectal carcinoma: a meta-analysis. Jpn J Clin Oncol 2013;43(10):988–95.
13. Luo C, Yuan R, Chen L, Zhou W, Shen W, Qiu Y, et al. TAB3 upregulates Survivin expression to pro- mote colorectal cancer invasion and metastasis by binding to the TAK1-TRAF6 complex. Oncotarget 2017;8(63):106565–76.
14. Dong D, Jiang W, Lei J, Chen L, Liu X, Ge J, et al. Ubiq- uitin-like protein FAT10 promotes bladder cancer progression by stabilizing survivin. Oncotarget. 2016 Dec 6;7(49):81463–73.
15. Lin Y, Zhong H, Sun B, Peng Y, Lu F, Chen M, et al. USP22 promotes proliferation in renal cell carcinoma by stabilizing survivin. Oncol Lett 2020;20(5):246.
16. Qi G, Kudo Y, Tang B, Liu T, Jin S, Liu J, et al. PARP6 acts as a tumor suppressor via downregulating Sur- vivin expression in colorectal cancer. Oncotarget 2016;7(14):18812–24.
17. Wang H, Li S, Luo X, Song Z, Long X, Zhu X. Knock- down of PARP6 or survivin promotes cell apoptosis and inhibits cell invasion of colorectal adenocarci- noma cells. Oncol Rep 2017;37(4):2245–51.
18. Jakubowska K, Pryczynicz A, Dymicka-Piekarska V, Famulski W, Guzińska-Ustymowicz K. Immunohis- tochemical expression and serum level of survivin protein in colorectal cancer patients. Oncol Lett 2016;12(5):3591–7.
19. Krieg A, Werner TA, Verde PE, Stoecklein NH, Knoe- fel WT. Prognostic and clinicopathological signifi- cance of survivin in colorectal cancer: a meta-analysis. PLos One 2013;8(6):e65338.
20. Lee YY, Yu CP, Lin CK, Nieh S, Hsu KF, Chiang H, et al. Expression of survivin and cortactin in colorectal adenocarcinoma: association with clinicopathological parameters. Dis Markers 2009;26(1):9–18.
21. Ponnelle T, Chapusot C, Martin L, Bouvier AM, Plenchette S, Faivre J, et al. Cellular localisation of sur- vivin: impact on the prognosis in colorectal cancer. J Cancer Res Clin Oncol 2005;131(8):504–10.
22. Qi G, Tuncel H, Aoki E, Tanaka S, Oka S, Kaneko I, et al. Intracellular localization of survivin determines biological behavior in colorectal cancer. Oncol Rep 2009;22(3):557–62.
23. Sarela AI, Macadam RC, Farmery SM, Markham AF, Guillou PJ. Expression of the antiapoptosis gene, sur- vivin, predicts death from recurrent colorectal carci- noma. Gut 2000;46(5):645–50.
24. Fang YJ, Lu ZH, Wang GQ, Pan ZZ, Zhou ZW, Yun JP, et al. Elevated expressions of MMP7, TROP2, and sur- vivin are associated with survival, disease recurrence, and liver metastasis of colon cancer. Int J Colorectal Dis 2009;24(8):875–84.